Myelodysplastic Syndrome clinical trials at UC Irvine

• Collection of Samples From Patients With MDS

  open to eligible people ages 18 years and up

  The purpose of this study is to collect information and bone marrow, blood, saliva, cheek cells and skin to be used in the laboratory to assist the sponsor in identifying a new way of treating MDS.

  Irvine, California and other locations

• Ibrutinib and Azacitidine for Treatment of Higher Risk Myelodysplastic Syndrome

  Sorry, in progress, not accepting new patients

  This phase Ib trial studies the side effects and best dose of ibrutinib when given together with azacitidine in treating patients with myelodysplastic syndrome that is likely to occur or spread (higher risk) and who were previously treated or untreated and unfit for or refused intense therapy. Ibrutinib and azacitidine may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.

  Orange, California and other locations

Last updated: March 9, 2020